WVVI vs NBY vs AYTU vs PRPH

For growth investors, Aytu BioPharma, Inc.

(AYTU) is the stronger pick with 1. 8% revenue growth year-over-year, versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ProPhase Labs, Inc.

(PRPH) delivered a total return of -63. 2%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PRPH returned +37. 5% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Willamette Valley Vineyards, Inc.

(WVVI) is the lower-risk stock at -0. 25β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -1067% more volatile than WVVI relative to the S&P 500. On balance sheet safety, Willamette Valley Vineyards, Inc. (WVVI) carries a lower debt/equity ratio of 23% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aytu BioPharma, Inc.

(AYTU) is pulling ahead at 1. 8% versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, NBY leads at -1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Willamette Valley Vineyards, Inc.

(WVVI) is the more profitable company, earning -3. 3% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps -3. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WVVI leads at -2. 4% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, WVVI (100.

0% yield) pays a dividend. NBY, AYTU, PRPH do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Willamette Valley Vineyards, Inc.

(WVVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 25), 100. 0% yield). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WVVI: -59. 3%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WVVI (Consumer Defensive) and NBY (Healthcare) and AYTU (Healthcare) and PRPH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WVVI is a small-cap income-oriented stock; NBY is a small-cap quality compounder stock; AYTU is a small-cap quality compounder stock; PRPH is a small-cap quality compounder stock. WVVI pays a dividend while NBY, AYTU, PRPH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.